1206775-11-2

Upstream product

• 102294-59-7 N-(4-iodophenyl)-methanesulfonamide 
• 4627-10-5 4,4,6-trimethyl-2-vinyl-1,3,2-dioxaborinane 

Downstream Products

• 1252662-55-7 C₁₉H₂₀BrNO₃S 
• 1206773-88-7 N-[4-[(E)-2-[2-methoxy-3-(3-methyloxetan-3-yl)-5-(2-oxo-1H-pyridin-3-yl)phenyl]vinyl]phenyl]methanesulfonamide 
• 1232361-30-6 N-[4-[(E)-2-[3-tert-butyl-2-methoxy-5-(6-oxo-1H-pyridazin-5-yl)phenyl]vinyl]phenyl]methanesulfonamide 
• 1206773-86-5 N-[4-[(E)-2-[3-(2-hydroxy-1,1-dimethylethyl)-2-methoxy-5-(2-oxo-1H-pyridin-3-yl)phenyl]vinyl]phenyl]methanesulfonamide 
• 1206773-16-1 N-(4-{2-[3-tert-butyl-6-hydroxy-2-methoxy-5-(2-oxo-1,2-dihydro-pyridin-3-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide 
• 1206772-62-4 N-(4-{(E)-2-[3-(1-hydroxymethyl-cyclopropyl)-5-(2-oxo-1,2-dihydro-pyridin-3-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide 

Relevant academic research and scientific papers

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV in

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds having the formula I wherein R1, R2, R3, R4, R5a, R5b, R5c and R6 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are